Related Experiment Videos
New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials
1MCP-Hahnemann School of Medicine and Allegheny University of the Health Sciences, Philadelphia, PA 19102-1192, USA.
Insights
Aspirin and heparin help reduce risks after plaque rupture, but novel antithrombotic treatments offer improved options for acute coronary syndromes. These new therapies show benefits in clinical trials.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Thrombosis following atherosclerotic plaque rupture is a primary cause of acute coronary syndromes (ACS), including unstable angina and myocardial infarction.
- Current treatments like aspirin and heparin reduce ischemic events but have limitations, necessitating exploration of advanced antithrombotic strategies.
- Persistent coagulation abnormalities post-ACS suggest a need for long-term anticoagulation, which is challenging with traditional therapies like heparin due to monitoring requirements.
Purpose of the Study:
- To review the limitations of current antithrombotic therapies for acute coronary syndromes.
- To highlight the development and demonstrated benefits of novel antithrombotic treatments in managing ACS.
Main Methods:
- Review of existing literature on antithrombotic treatments for acute coronary syndromes.
- Analysis of randomized clinical trial data for novel antithrombotic agents.
Main Results:
- Aspirin and heparin combination therapy effectively reduces symptomatic and asymptomatic ischemia, myocardial infarction, and mortality in ACS patients.
- Heparin's utility is restricted to short-term, in-hospital use due to monitoring needs and bleeding risks.
- Novel antithrombotic agents, including direct thrombin inhibitors, platelet fibrinogen receptor antagonists, and low-molecular-weight heparins, have shown significant benefits in recent clinical trials.
Conclusions:
- While aspirin and heparin are foundational, their limitations drive the need for improved antithrombotic therapies.
- Novel antithrombotic treatments represent a significant advancement in managing acute coronary syndromes, offering potentially safer and more effective long-term solutions.
Abstract:
Thrombosis after the rupture of an atherosclerotic plaque often precipitates the acute coronary syndromes of unstable angina and myocardial infarction. The combination of aspirin and heparin has been shown to reduce the occurrence of both symptomatic and asymptomatic ("silent") ischemia, myocardial infarction, and death in patients with these syndromes. However, heparin and aspirin each have significant limitations as antithrombotic drugs. Additionally, coagulation abnormalities may persist for several months after an acute ischemic event, and long-term anticoagulation may be beneficial. Because of the need for frequent anticoagulation monitoring and dosage adjustment, the use of heparin is limited to short-term treatment during the acute in-hospital phase. Recently several novel antithrombotic treatments have been developed. The benefits of direct thrombin inhibitors, platelet fibrinogen receptor antagonists, and low-molecular-weight heparins in the treatment of acute coronary syndromes have been demonstrated in randomized clinical trials.